(135 days)
Not Found
No
The document describes a laser light scattering system for detecting platelet aggregation and does not mention any AI or ML components in the device description, intended use, or performance studies.
No
The device aids in the detection of platelet dysfunction due to aspirin ingestion, which is a diagnostic purpose, not a therapeutic one. It measures the level of platelet aggregation and does not treat or prevent any condition.
Yes
Explanation: The "Intended Use / Indications for Use" section states that the device is a "qualitative system to aid in the detection of platelet dysfunction due to aspirin ingestion." This indicates its role in diagnosing a specific physical condition.
No
The device description explicitly states that the system consists of an instrument and a disposable assay cartridge, indicating the presence of hardware components beyond just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's a "qualitative system to aid in the detection of platelet dysfunction due to aspirin ingestion... in 3.2% citrated venous whole blood". This indicates it's used to examine a sample taken from the human body (whole blood) to provide information about a physiological state (platelet dysfunction).
- Sample Type: It uses "3.2% citrated venous whole blood", which is a biological sample taken from a patient.
- Purpose: The purpose is to "aid in the detection of platelet dysfunction", which is a diagnostic purpose.
- Device Description: The device description explains how it measures "the level of platelet aggregation induced by arachidonic acid agonist in whole blood". This is a measurement performed on a biological sample.
- Professional Use: While it requires professional use, this is common for many IVDs.
The definition of an IVD generally includes devices used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device clearly fits that description.
N/A
Intended Use / Indications for Use
The AggreGuide A-100 AA Assay is a qualitative system to aid in the detection of platelet dysfunction due to aspirin ingestion by those 18 years of age or older in 3.2% citrated venous whole blood using the AggreGuide A-100 instrument. For professional use. This test is not for use in patients with underlying congenital platelet abnormalities, patients with non-aspirin induced acquired platelet abnormalities or in patients receiving non-aspirin anti-platelet agents. The test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician.
Product codes
JOZ
Device Description
The AggreGuide A-100 is a laser light scattering system that detects the level of platelet aggregation induced by arachidonic acid agonist in whole blood in motion. The system consists of an instrument and a disposable assay cartridge with pre-loaded freeze dried agonist. A whole blood sample is added to a disposable cartridge that is preloaded with freeze dried arachidonic acid agonist (AA) in a reaction chamber for an individual test. The amount of platelet aggregation is measured by detecting the laser light scattering caused by platelet aggregates. Aspirin is known to inhibit the level of platelet aggregation, or activity, when blood is mixed with arachidonic acid.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
18 years of age or older
Intended User / Care Setting
For professional use.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The risk analysis method used to assess the impact of the modifications was ISO 14971:2007, "Medical devices -- Application of risk management to medical devices".
Additional modification-specific criteria were applied to each modification as necessary and as noted in the body of the 510(k).
The results of the laser diode part replacement verification and validation activities demonstrated acceptable performance.
The results of the QC2 implementation process and verification and validation activities demonstrated acceptable performance.
The results of software and design verification and validation activities demonstrated acceptable performance.
The results from stability testing using an isochronous testing paradigm supported the shelf-life extension to 18 months based on acceptance criteria of ±1 PAI unit.
The results of User's Manual revision activities showed acceptable validation and verification results.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 864.5700 Automated platelet aggregation system.
(a)
Identification. An automated platelet aggregation system is a device used to determine changes in platelet shape and platelet aggregation following the addition of an aggregating reagent to a platelet-rich plasma.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's name in a circular arrangement around an emblem. The emblem consists of a stylized human figure with three faces, representing the department's focus on health and well-being. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 5, 2017
Aggredyne, Inc. Mr. Philip C. Speros Chief Operating Officer 10530 Rockley Road Houston, Texas 77099
Re: K163274
Trade Name: AggreGuide A-100 AA Assay, AggreGuide A-100 Instrument Regulation Number: 21 CFR 864.5700 Regulation Name: Automated platelet aggregation system Regulatory Class: Class II Product Code: JOZ Dated: November 18, 2016 Received: November 21, 2016
Dear Mr. Speros:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting of medical device-related
1
adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/ Industry/default.htm.
Sincerely yours,
Leonthena R. Carrington -S
Lea Carrington, MS, MBA, MT(ASCP) Director
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K163274
Device Name AggreGuide A-100 AA assay AggreGuide A-100 Instrument
Indications for Use (Describe)
The AggreGuide A-100 AA Assay is a qualitative system to aid in the detection of platelet dysfunction due to aspirin ingestion by those 18 years of age or older in 3.2% citrated venous whole blood using the AggreGuide A-100 instrument. For professional use. This test is not for use in patients with underlying congenital platelet abnormalities, patients with non-aspirin induced acquired platelet abnormalities or in patients receiving non-aspirin anti-platelet agents. The test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
This 510(k) summary is submitted in accordance with the requirements of 21 CFR 807.92(c).
1. Submitter
| Name: | Aggredyne, Inc. |
|---|---|
| Address: | 10530 Rockley Road |
| Suite 150 | |
| Houston, TX 99077 | |
| Phone: | 713-636-5996 |
| 866-800-1955 | |
| Contact: | Philip Speros, Ph.D. |
| psperos@aggredyne.com |
2. Device
| Trade Name(s): | AggreGuide A-100 AA assay |
|---|---|
| AggreGuide A-100 Instrument | |
| Common Name: | Platelet aggregation test |
The AggreGuide A-100 AA assay and AggreGuide A-100 Instrument are classified as Class II. No performance standards have been established under Section 514 of the Food, Drug and Cosmetic Act for automated platelet aggregation test systems. Product Code: JOZ 21 CFR 864.5700 Regulation Number:
Classification Name: System, Automated Platelet Aggregation
3. Predicate Device
The predicate device(s) used for the determination of substantial equivalence are the previously-cleared AggreGuide A-100 AA assay and AggreGuide A-100 Instrument, 510(k) document number K122162.
4. Device Description
The AggreGuide A-100 is a laser light scattering system that detects the level of platelet aggregation induced by arachidonic acid agonist in whole blood in motion. The system consists of an instrument and a disposable assay cartridge with pre-loaded freeze dried agonist. A whole blood sample is added to a disposable cartridge that is preloaded with freeze dried arachidonic acid agonist (AA) in a reaction chamber for an individual test. The amount of platelet aggregation is measured by detecting the laser light scattering caused by platelet aggregates. Aspirin is known to inhibit the level of platelet aggregation, or activity, when blood is mixed with arachidonic acid.
5. Indications for Use
The AggreGuide A-100 AA Assay is a qualitative system to aid in the detection of platelet dysfunction due to aspirin ingestion by those 18 years of age or older in 3.2% citrated venous whole blood using the AggreGuide A-100 instrument. For professional use. This test is not for use in patients with underlying congenital platelet abnormalities, patients with non-aspirin induced acquired platelet abnormalities or in patients receiving non-aspirin anti-platelet agents. The test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician.
4
6. Comparison with Predicate Device
The predicate device(s) used for the determination of substantial equivalence are the previously-cleared AggreGuide A-100 AA assay and AggreGuide A-100 Instrument, 510(k) document number K122162.
| Item | Predicate Device (K122162) | Current Device |
|---|---|---|
| Device Name | AggreGuide A-100 | Same |
| Regulation Number | 864.5700 | Same |
| Product Code | JOZ | Same |
| Principle of Operation | Platelet aggregation with detection of laser light scattering | Same |
| Indications for Use | The AggreGuide A-100 AA Assay is a qualitative system to aid in the detection of platelet dysfunction due to aspirin ingestion by those 18 years of age or older in 3.2% citrated venous whole blood using the AggreGuide A-100 instrument. For professional use. This test is not for use in patients with underlying congenital platelet abnormalities, patients with non-aspirin induced acquired platelet abnormalities or in patients receiving non-aspirin anti-platelet agents. The test results should be interpreted in conjunction with other clinical and laboratory data available to the clinician. | Same |
| Intended Use | The AggreGuide device is intended for patients for whom detecting platelet dysfunction in response to arachidonic acid may be desirable, such as those who are on or are candidates for antiplatelet therapy. | Same |
| Specimen Type | 3.2% sodium citrate-anticoagulated whole blood | Same |
| Test Cartridges | Single-use disposable | Same |
| Agonist Concentration | ||
| Used for Platelet | ||
| Activation | Arachidonic Acid, 1 mM | Same |
| Test Procedure | Manual addition of blood sample to test cartridge, automated assay and generation of results | Same |
| Time to Result | 5 minutes | Same |
| Sample Volume | ||
| Required | 164 μL | Same |
| Results Displayed | Platelet Activity Index (PAI) | Same |
| Calibration | Performed at Factory | Same |
| Sterility | Not sterile | Same |
| Laser Diode Part | Sanyo DL-4140-001S | QSI QL7816SA-L |
| Quality Control | ||
| Cartridge | QC quality control cartridge for instrument self-check | Modified quality control QC2 |
| cartridge | ||
| Software | Version 4.91 | Version 5.10 |
| Test Cartridge Shelf Life | 12 months | 18months |
| User's Manual | LBL-0014-C | LBL-0014-E |
5
7. Summary of Performance Data
The risk analysis method used to assess the impact of the modifications was ISO 14971:2007, "Medical devices -- Application of risk management to medical devices".
Additional modification-specific criteria were applied to each modification as necessary and as noted in the body of the 510(k).
The results of the laser diode part replacement verification and validation activities demonstrated acceptable performance.
The results of the QC2 implementation process and verification and validation activities demonstrated acceptable performance.
The results of software and design verification and validation activities demonstrated acceptable performance.
The results from stability testing using an isochronous testing paradigm supported the shelf-life extension to 18 months based on acceptance criteria of ±1 PAI unit.
The results of User's Manual revision activities showed acceptable validation and verification results.
8. Conclusions
The modified AggreGuide A-100 AA assay and AggreGuide A-100 Instrument have the following similarities to those which previously received 510(k) clearance:
- have the same indicated use,
- use the same operating principle,
- . incorporate the same basic design,
- . incorporate the same reagents, and
- . are packaged using the same materials and processes.
The modifications did not require collection of clinical performance data. In addition, the results of design verification and validation tests do not raise new issues of safety and effectiveness.
In summary, the AggreGuide A-100 AA assay and AggreGuide A-100 Instrument described in this submission are, in our opinion, substantially equivalent to the predicate device.